<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174252</url>
  </required_header>
  <id_info>
    <org_study_id>A6281234</org_study_id>
    <nct_id>NCT00174252</nct_id>
  </id_info>
  <brief_title>Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age</brief_title>
  <official_title>Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation, Treated by Genotonorm Especially Evolution After Dose Adaptation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the percentage of children with serum IGF-1 &gt; 2 standard deviation (compared to a
      child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12
      months after initiation of GH treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Children With Insulin Growth Factor-1 (IGF-1) &gt; 2 Standard Deviation (SD) at 9 and 12 Months</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Percentage of children with serum IGF-1 &gt; 2 SD (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment. 9 months and 12 months are combined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>The height in SD was calculated using Sempe reference means and standard deviations for height. Change in height SD was calculated as height in SD at &quot;12 months&quot; minus height in SD at &quot;Baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at &quot;24 months&quot; minus height in SD at &quot;Baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Height SD CA From Baseline at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>Baseline, 12 and 24 months</time_frame>
    <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at &quot;12 or 24 months&quot; minus height in SD at &quot;Baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at &quot;12 months&quot; minus height in SD at &quot;Baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at &quot;24 months&quot; minus height in SD at &quot;Baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Height SD BA From Baseline at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>Baseline, 12 and 24 months</time_frame>
    <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at &quot;12 or 24 months&quot; minus height in SD at &quot;Baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Growth rate SD CA at 12 months was calculated as:(Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD CA at 24 months was calculated as:(Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Growth rate SD CA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD CA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for BA at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for BA at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Growth Rate SD (BA) at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for CA at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in Height SD (CA) was calculated as:
Height SD (CA) at 12 months minus Height SD (CA) at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANCOVA for Height SD CA at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Height SD (CA) at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANCOVA for Height SD BA at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in Height SD (BA) was calculated as:
Height SD (BA) at 12 months minus Height SD (BA) at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANCOVA for Height SD BA at 24 Months in Children With IGF-1 &lt;= 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Height SD (BA) at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>6, 9, 12, 15, 18, 21, and 24 months</time_frame>
    <description>IGF-1 SD was calculated at each study time point using gender specific IGF-1 reference mean and SD for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 minus reference mean) divided by reference SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>6, 9, 12, 15, 18, 21, and 24 months</time_frame>
    <description>IGF-1 SD was calculated at each study time point using these gender specific IGF-1 reference means and SDs for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 - reference mean) / reference SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1/Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio at 12 and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1/IGFBP-3 Ratio at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <arm_group>
    <arm_group_label>Genotonorm (Somatropin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genotonorm (Somatropin)</intervention_name>
    <description>0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years</description>
    <arm_group_label>Genotonorm (Somatropin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronological age between 4 and 9 years for a boy and 4 and 7 years for a girl.

          -  Measured Height &lt; -2.5 Standard Deviation

        Exclusion Criteria:

          -  Pubertal signs ie: testis volume &gt; or = 4 ml in boys and breast stage &gt; or = B2
             (Tanner)

          -  Serious chronic disease (diabetes, renal insufficiency, heart failure, hepatic
             insufficiency, neoplasia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amiens</city>
        <zip>80030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>ANGERS Cedex 03</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caen Cedex 5</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dunkerque Cedex 1</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>PARIS Cedex 19</city>
        <zip>75935</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31026</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6281234&amp;StudyName=Study%20Aimed%20At%20Improving%20Height%20With%20Genotonorm%20In%20Children%20Born%20Little%20And/Or%20Light%20With%20Growth%20Retardation%20At%20The%20Age</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>April 2, 2010</results_first_submitted>
  <results_first_submitted_qc>May 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2010</results_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Genotonorm</title>
          <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Genotonorm</title>
          <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 4 and 8 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 8 and 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Height From Baseline</title>
        <description>The standing height measurements were performed at the same time of the day by using a wallmounted device (e.g. Harpenden Stadiometer) at each study visit. The pre-specified clinical outcomes were analyzed at 12 and 24 months.</description>
        <time_frame>Baseline, 12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with evaluable height data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height From Baseline</title>
          <description>The standing height measurements were performed at the same time of the day by using a wallmounted device (e.g. Harpenden Stadiometer) at each study visit. The pre-specified clinical outcomes were analyzed at 12 and 24 months.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with evaluable height data at 12 and 24 months.</population>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Children With Insulin Growth Factor-1 (IGF-1) &gt; 2 Standard Deviation (SD) at 9 and 12 Months</title>
        <description>Percentage of children with serum IGF-1 &gt; 2 SD (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment. 9 months and 12 months are combined.</description>
        <time_frame>9 and 12 months</time_frame>
        <population>The safety analysis set (SAS) was defined as all patients who received at least one dose of GH treatment. Number of Participants Analyzed = Number of children treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children With Insulin Growth Factor-1 (IGF-1) &gt; 2 Standard Deviation (SD) at 9 and 12 Months</title>
          <description>Percentage of children with serum IGF-1 &gt; 2 SD (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment. 9 months and 12 months are combined.</description>
          <population>The safety analysis set (SAS) was defined as all patients who received at least one dose of GH treatment. Number of Participants Analyzed = Number of children treated.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Applies to &quot;no&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>86.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.2</ci_lower_limit>
            <ci_upper_limit>93.7</ci_upper_limit>
            <estimate_desc>95% CI was estimated using the F-distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Applies to &quot;yes&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>14.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.3</ci_lower_limit>
            <ci_upper_limit>25.8</ci_upper_limit>
            <estimate_desc>95% confidence interval (CI) was estimated using the F-distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>The height in SD was calculated using Sempe reference means and standard deviations for height. Change in height SD was calculated as height in SD at &quot;12 months” minus height in SD at &quot;Baseline&quot;.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>The full analysis set (FAS) included all patients who received at least one dose of assigned treatment and had at least one subsequent rating of IGF-1. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable height SD CA data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>The height in SD was calculated using Sempe reference means and standard deviations for height. Change in height SD was calculated as height in SD at &quot;12 months” minus height in SD at &quot;Baseline&quot;.</description>
          <population>The full analysis set (FAS) included all patients who received at least one dose of assigned treatment and had at least one subsequent rating of IGF-1. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable height SD CA data at 12 months.</population>
          <units>SD for CA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “24 months” minus height in SD at &quot;Baseline&quot;.</description>
        <time_frame>Baseline, 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable height SD CA data at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “24 months” minus height in SD at &quot;Baseline&quot;.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable height SD CA data at 24 months.</population>
          <units>SD for CA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Height SD CA From Baseline at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “12 or 24 months” minus height in SD at “Baseline&quot;.</description>
        <time_frame>Baseline, 12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable Height SD CA data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height SD CA From Baseline at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “12 or 24 months” minus height in SD at “Baseline&quot;.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable Height SD CA data at 12 and 24 months.</population>
          <units>SD for BA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “12 months” minus height in SD at &quot;Baseline&quot;.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable height SD BA data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “12 months” minus height in SD at &quot;Baseline&quot;.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable height SD BA data at 12 months.</population>
          <units>SD for BA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “24 months” minus height in SD at “Baseline&quot;.</description>
        <time_frame>Baseline, 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable height SD BA data at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “24 months” minus height in SD at “Baseline&quot;.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable height SD BA data at 24 months.</population>
          <units>Height in SD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Height SD BA From Baseline at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “12 or 24 months” minus height in SD at “Baseline&quot;.</description>
        <time_frame>Baseline, 12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 or 12 months with evaluable height SD BA data at 12 and 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height SD BA From Baseline at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at “12 or 24 months” minus height in SD at “Baseline&quot;.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 or 12 months with evaluable height SD BA data at 12 and 12 months.</population>
          <units>SD for BA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Growth Rate at 12 and 24 Months</title>
        <description>Growth Rate was calculated at 12 months as:
(Height at 12 months minus Height at Day 0) divided by {(Date of 12 months minus Date of Day 0) divided by 365.25}
Growth Rate was calculated at 24 months as:
(Height at 24 months minus Height at 12 months) divided by {(Date of 24 months minus Date of 12 months) divided by 365.25}</description>
        <time_frame>12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children treated. n = Number of children with evaluable growth rate data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Rate at 12 and 24 Months</title>
          <description>Growth Rate was calculated at 12 months as:
(Height at 12 months minus Height at Day 0) divided by {(Date of 12 months minus Date of Day 0) divided by 365.25}
Growth Rate was calculated at 24 months as:
(Height at 24 months minus Height at 12 months) divided by {(Date of 24 months minus Date of 12 months) divided by 365.25}</description>
          <population>FAS. Number of Participants Analyzed = Number of children treated. n = Number of children with evaluable growth rate data at 12 and 24 months.</population>
          <units>cm/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.06" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>Growth rate SD CA at 12 months was calculated as:(Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD CA at 24 months was calculated as:(Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months</description>
        <time_frame>12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable growth rate SD CA data at 12 months. n = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable growth rate SD CA data at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>Growth rate SD CA at 12 months was calculated as:(Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD CA at 24 months was calculated as:(Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable growth rate SD CA data at 12 months. n = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable growth rate SD CA data at 24 months.</population>
          <units>SD for CA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>Growth rate SD CA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD CA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months</description>
        <time_frame>12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable growth rate SD CA data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>Growth rate SD CA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD CA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable growth rate SD CA data at 12 and 24 months.</population>
          <units>SD for CA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for BA at 12 months</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable growth rate SD BA data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for BA at 12 months</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable growth rate SD BA data at 12 months.</population>
          <units>SD for CA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for BA at 24 months</description>
        <time_frame>Baseline, 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable growth rate SD BA data at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for BA at 24 months</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable growth rate SD BA data at 24 months.</population>
          <units>SD for BA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Growth Rate SD (BA) at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for CA at 24 months</description>
        <time_frame>12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable growth rate SD BA data at 12 months. n = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable growth rate SD BA data at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Growth Rate SD (BA) at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for CA at 12 months
Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for CA at 24 months</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable growth rate SD BA data at 12 months. n = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable growth rate SD BA data at 24 months.</population>
          <units>SD for BA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Summary of Body Mass Index (BMI) at 12 and 24 Months</title>
        <description>BMI was calculated at 12 months and 24 months as: (Weight at 12 or 24 months divided by Height at 12 or 24 months) squared</description>
        <time_frame>12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children treated. n = Number of children with evaluable BMI data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Body Mass Index (BMI) at 12 and 24 Months</title>
          <description>BMI was calculated at 12 months and 24 months as: (Weight at 12 or 24 months divided by Height at 12 or 24 months) squared</description>
          <population>FAS. Number of Participants Analyzed = Number of children treated. n = Number of children with evaluable BMI data at 12 and 24 months.</population>
          <units>kg/meters squared (m2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>Change in Height SD (CA) was calculated as:
Height SD (CA) at 12 months minus Height SD (CA) at Baseline</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months or with IGF-1 &gt; 2 SD at 9 and 12 months and with evaluable height SD CA data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm (IGF-1 &lt; = 2 SD at 9 or 12 Months)</title>
          </group>
          <group group_id="O2">
            <title>Genotonorm (IGF-1 &gt; 2 SD at 9 and 12 Months)</title>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>Change in Height SD (CA) was calculated as:
Height SD (CA) at 12 months minus Height SD (CA) at Baseline</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months or with IGF-1 &gt; 2 SD at 9 and 12 months and with evaluable height SD CA data at 12 months.</population>
          <units>SD for CA</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="0.04"/>
                    <measurement group_id="O2" value="-1.59" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for height SD at baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ANCOVA for Height SD CA at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>Height SD (CA) at 24 months.</description>
        <time_frame>Baseline, 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months or with IGF-1 &gt; 2 SD at 9 and 12 months and with evaluable height SD CA data at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm (IGF-1 &lt; = 2 SD at 9 or 12 Months)</title>
          </group>
          <group group_id="O2">
            <title>Genotonorm (IGF-1 &gt; 2 SD at 9 and 12 Months)</title>
          </group>
        </group_list>
        <measure>
          <title>ANCOVA for Height SD CA at 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>Height SD (CA) at 24 months.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months or with IGF-1 &gt; 2 SD at 9 and 12 months and with evaluable height SD CA data at 24 months.</population>
          <units>SD for CA</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="0.06"/>
                    <measurement group_id="O2" value="-1.18" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>Bilateral test multiple comparison threshold for statistical significance = 0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted for height SD at baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ANCOVA for Height SD BA at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>Change in Height SD (BA) was calculated as:
Height SD (BA) at 12 months minus Height SD (BA) at Baseline</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months or with IGF-1 &gt; 2 SD at 9 and 12 months and with evaluable height SD BA data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm (IGF-1 &lt; = 2 SD at 9 or 12 Months)</title>
          </group>
          <group group_id="O2">
            <title>Genotonorm (IGF-1 &gt; 2 SD at 9 and 12 Months)</title>
          </group>
        </group_list>
        <measure>
          <title>ANCOVA for Height SD BA at 12 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>Change in Height SD (BA) was calculated as:
Height SD (BA) at 12 months minus Height SD (BA) at Baseline</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months or with IGF-1 &gt; 2 SD at 9 and 12 months and with evaluable height SD BA data at 12 months.</population>
          <units>SD for BA</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.22"/>
                    <measurement group_id="O2" value="0.76" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for height SD at baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.20</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ANCOVA for Height SD BA at 24 Months in Children With IGF-1 &lt;= 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>Height SD (BA) at 24 months</description>
        <time_frame>Baseline, 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months or with IGF-1 &gt; 2 SD at 9 and 12 months and with evaluable height SD BA data at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm (IGF-1 &lt; = 2 SD at 9 or 12 Months)</title>
          </group>
          <group group_id="O2">
            <title>Genotonorm (IGF-1 &gt; 2 SD at 9 and 12 Months)</title>
          </group>
        </group_list>
        <measure>
          <title>ANCOVA for Height SD BA at 24 Months in Children With IGF-1 &lt;= 2 SD at 9 or 12 Months and IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>Height SD (BA) at 24 months</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months or with IGF-1 &gt; 2 SD at 9 and 12 months and with evaluable height SD BA data at 24 months.</population>
          <units>SD for BA</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.25"/>
                    <measurement group_id="O2" value="0.64" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.325</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for height SD at baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in BA From Baseline at 12 and 24 Months</title>
        <description>Change in BA was calculated as: (12 or 24 months minus Screening)</description>
        <time_frame>Baseline, 12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children treated. n = Number of children with evaluable BA data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BA From Baseline at 12 and 24 Months</title>
          <description>Change in BA was calculated as: (12 or 24 months minus Screening)</description>
          <population>FAS. Number of Participants Analyzed = Number of children treated. n = Number of children with evaluable BA data at 12 and 24 months.</population>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BA/CA at 12 and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.</description>
        <time_frame>12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable BA/CA data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>BA/CA at 12 and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable BA/CA data at 12 and 24 months.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BA/CA at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.</description>
        <time_frame>12 and 24 months</time_frame>
        <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable BA/CA data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>BA/CA at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.</description>
          <population>FAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable BA/CA data at 12 and 24 months.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <description>IGF-1 SD was calculated at each study time point using gender specific IGF-1 reference mean and SD for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 minus reference mean) divided by reference SD</description>
        <time_frame>6, 9, 12, 15, 18, 21, and 24 months</time_frame>
        <population>SAS. Number of Participants Analyzed = Number of children treated. n = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable IGF-1 SD data at 6, 9, 12, 15, 18, 21, and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <description>IGF-1 SD was calculated at each study time point using gender specific IGF-1 reference mean and SD for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 minus reference mean) divided by reference SD</description>
          <population>SAS. Number of Participants Analyzed = Number of children treated. n = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable IGF-1 SD data at 6, 9, 12, 15, 18, 21, and 24 months.</population>
          <units>SD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Months (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 Months (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <description>IGF-1 SD was calculated at each study time point using these gender specific IGF-1 reference means and SDs for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 – reference mean) / reference SD</description>
        <time_frame>6, 9, 12, 15, 18, 21, and 24 months</time_frame>
        <population>SAS. Number of Participants Analyzed = Number of children treated. n = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable IGF-1 SD data at 6, 9, 12, 15, 18, 21, and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <description>IGF-1 SD was calculated at each study time point using these gender specific IGF-1 reference means and SDs for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 – reference mean) / reference SD</description>
          <population>SAS. Number of Participants Analyzed = Number of children treated. n = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable IGF-1 SD data at 6, 9, 12, 15, 18, 21, and 24 months.</population>
          <units>SD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 Months (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IGF-1/Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio at 12 and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
        <time_frame>12 and 24 months</time_frame>
        <population>SAS. Number of Participants Analyzed = Number of children treated. n = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable IGF-1/IGFBP-3 data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>IGF-1/Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio at 12 and 24 Months in Children With IGF-1 &lt; = 2 SD at 9 or 12 Months</title>
          <population>SAS. Number of Participants Analyzed = Number of children treated. n = Number of children with IGF-1 &lt; = 2 SD at 9 or 12 months with evaluable IGF-1/IGFBP-3 data at 12 and 24 months.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IGF-1/IGFBP-3 Ratio at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
        <time_frame>12 and 24 months</time_frame>
        <population>SAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable IGF-1/IGFBP-3 data at 12 and 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotonorm</title>
            <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>IGF-1/IGFBP-3 Ratio at 12 and 24 Months in Children With IGF-1 &gt; 2 SD at 9 and 12 Months</title>
          <population>SAS. Number of Participants Analyzed = Number of children with IGF-1 &gt; 2 SD at 9 and 12 months with evaluable IGF-1/IGFBP-3 data at 12 and 24 months.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Genotonorm</title>
          <description>Initiated at a dose of 0.40 milligrams (mg)/kilograms (kg) of Genotonorm divided in 7 daily subcutaneous injections and titrated as needed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Amniotic band syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Microcytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>House dust allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Insulin-like growth factor increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sleep terror</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Adenotonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

